Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020092592 - THERAPEUTIC COMPOUNDS AND COMPOSITIONS

Publication Number WO/2020/092592
Publication Date 07.05.2020
International Application No. PCT/US2019/058896
International Filing Date 30.10.2019
IPC
A61K 31/122 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
12Ketones
122having the oxygen atom directly attached to a ring, e.g. quinones, vitamin K1, anthralin
A61K 31/407 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
40having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
407condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
Applicants
  • EXITHERA PHARMACEUTICALS, INC. [US]/[US]
Inventors
  • HAYWARD, Neil J.
  • CHENARD, Bertrand L.
  • XU, Yuelian
  • DOROW, Roberta L.
  • MATISON, Michael E.
  • KOLCHINSKI, Alexander
  • FORNICOLA, Richard
Agents
  • GUTIERREZ, Gregory Daniel
  • ARGENTIERI, Steven, R.
  • ASHRAF, Shovon
  • BRODOWSKI, Michael
  • BUCHMAN, Joshua, J.
Priority Data
62/752,50330.10.2018US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) THERAPEUTIC COMPOUNDS AND COMPOSITIONS
(FR) COMPOSÉS ET COMPOSITIONS THÉRAPEUTIQUES
Abstract
(EN)
The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of making these compounds or pharmaceutically acceptable salts thereof and compositions and methods of use thereof.
(FR)
La présente invention concerne des composés qui inhibent le Facteur XIa ou la kallicréine ainsi que des sels pharmaceutiquement acceptables de ceux-ci et des compositions de ceux-ci. La présente invention concerne également des procédés de production de ces composés ou de leurs sels pharmaceutiquement acceptables ainsi que des compositions et des procédés d'utilisation de ceux-ci.
Latest bibliographic data on file with the International Bureau